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Abstract
IMPORTANCE—The finding of factors that differentially predict the likelihood of response to 
placebo over that of an active drug could have a significant impact on study design in this 
population.
OBJECTIVE—To identify possible nonspecific, baseline predictors of response to intervention in 
a large randomized clinical trial of children and adolescents with autism spectrum disorders.
DESIGN, SETTING, AND PARTICIPANTS—Randomized clinical trial of citalopram 
hydrobromide for children and adolescents with autism spectrum disorders and prominent 
repetitive behavior. Baseline data at study entry were examined with respect to final outcome to 
determine if response predictors could be identified. A total of 149 children and adolescents 5 to 
17 years of age (mean [SD] age, 9.4 [3.1] years) from 6 academic centers were randomly assigned 
to citalopram (n = 73) or placebo (n = 76). Participants had autistic disorder, Asperger syndrome, 
or pervasive developmental disorder, not otherwise specified; had illness severity ratings that were 
moderate or more than moderate on the Clinical Global Impression–Severity scale; and scored 
moderate or more than moderate on compulsive behaviors measured with the modified Children’s 
Yale-Brown Obsessive-Compulsive Scale.
INTERVENTIONS—Twelve weeks of treatment with citalopram (10 mg/5 mL) or placebo. The 
mean (SD) maximum dose of citalopram was 16.5 (6.5) mg by mouth daily (maximum dose, 20 
mg/d).
MAIN OUTCOMES AND MEASURES—A positive response was defined as having a score of 
at least much improved on the Clinical Global Impression–Improvement scale at week 12. 
Baseline measures included demographic (sex, age, weight, and pubertal status), clinical, and 
family measures. Clinical variables included baseline illness severity ratings (the Aberrant 
Behavior Checklist, the Child and Adolescent Symptom Inventory, the Vineland Adaptive 
Behavior Scales, the Repetitive Behavior Scale–Revised, and the Children’s Yale-Brown 
Obsessive-Compulsive Scale). Family measures included the Caregiver Strain Questionnaire.
RESULTS—Several baseline predictors of response were identified, and a principal component 
analysis yielded 3 composite measures (disruptive behavior, autism/mood, and caregiver strain) 
that significantly predicted response at week 12. Specifically, participants in the placebo group 
were significantly less likely than participants in the citalopram group to respond at week 12 if 
they entered the study more symptomatic on each of the 3 composite measures, and they were at 
least 2 times less likely to be responders.
CONCLUSIONS AND RELEVANCE—This analysis suggests strategies that may be useful in 
anticipating and potentially mitigating the nonspecific response in randomized clinical trials of 
children and adolescents with autism spectrum disorders.
TRIAL REGISTRATION—clinicaltrials.gov Identifier: NCT00086645
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Autism is a neurobehavioral syndrome characterized by impairments in social 
communication, by unusual preoccupations or interests, and by stereotyped or repetitive 
behaviors. Although there are no medications yet approved specifically for any of these core 
deficits, the number of medications targeting behavioral symptoms in this population has 
increased significantly in recent years, and the majority of children with autism are treated 
with at least 1 psychotropic medication by the time they reach 8 years of age.1
Virtually every class of psychotropic medication has been explored, typically in an open-
label fashion, in search of treating some facet of autistic disorder. Moreover, at least 1 
positive case report can be found for an overwhelming number of therapeutics, including 
lysergic acid diethylamide.2 Over the past decade, increased efforts have been directed 
toward identifying safe and effective treatments for both core symptoms and associated, 
severely impairing symptoms such as self-injury, aggression, hyperactivity, and repetitive 
behaviors. As a result of the number of placebo-controlled studies that have been completed 
in recent years, one of the consistent findings is the recognition of the importance of the 
placebo response in this population.
Considerable interest was generated in the administration of secretin following the 
observation by Horvath and colleagues3 that it appeared to dramatically improve core social 
deficits in children with autism who had received the peptide in the course of an evaluation 
of gastrointestinal symptoms. A series of additional case reports quickly followed, and 
eventually several controlled trials were mounted to examine the effects of secretin.
From the experience that followed, including some 15 controlled trials and more than 600 
participants,4,5 it could be argued that treatment with secretin was associated with an 
improvement in a significant percentage of participants. However, the placebo condition 
uniformly delivered equal or better outcomes across all of these trials, and the sum of the 
evidence is that there is no therapeutic signal for secretin in autism.4,5 And although neither 
autism nor the symptom targets that have been the focus of clinical trials would seem 
particularly likely to be placebo responsive, it is clear that improvement is to be expected in 
many children and adolescents with autism who enter these studies.
Taken together, in controlled trials that have used dichotomous outcomes in children with 
autism for a variety of clinical targets, placebo response rates have ranged from just under 
20% to 50% (Figure 1).6–27 Similar results for childhood depression and for anxiety 
disorders have been reported.28–30 Indeed, the majority of variability between positive and 
negative trials in childhood depression is in the range of placebo response rates. Other 
factors implicated in higher placebo response rates in childhood depression include milder 
baseline illness severity, younger age, and number of study sites.28 Similarly, a 
reexamination of depression trials in adults suggest that evidence for the effectiveness of 
antidepressant medicines is correlated with more severe illness.31–33
Various factors have been advanced to account for placebo or nonspecific response in the 
population of children with autism, including the heightened expectancy in parents who 
enter their children in clinical trials against a backdrop of relentless media exposure and 
seemingly daily claims of curative interventions; a symptom pattern in autism that 
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commonly includes a waxing and waning course; and the attention, care, and structure that 
comes with participation in a clinical trial.34 In their recent analysis of moderators, 
mediators, and nonspecific predictors of response in 100 participants from the Research 
Units on Pediatric Psychopharmacology Autism Network risperidone trial, Arnold et al35 
observed that parent education and family income predicted positive outcome in both active 
and placebo conditions. A host of baseline behavioral ratings derived from the Child and 
Adolescent Symptom Inventory (CASI),36 including ratings for anxiety, bipolar symptoms, 
oppositional-defiant symptoms, stereotypy, and hyperactivity, negatively predicted outcome. 
Garcia and colleagues37 were also interested in identifying predictors and moderators of 
outcome in the Pediatric Obsessive Compulsive Treatment Study, and after an excellent 
review, they identified demographic factors (sex, age, and household income), severity of 
illness markers (baseline severity of obsessive-compulsive disorder, functional impairment, 
and insight), comorbidity (internalizing diagnosis, externalizing diagnosis, anxiety 
symptoms, and externalizing symptoms), and family factors (parental psychopathology, 
family history of obsessive-compulsive disorder, family functioning, and accommodation) as 
relevant predictors or moderators of outcome. In their study of 112 participants,37 baseline 
severity of obsessive-compulsive disorder, functional impairment, insight, externalizing 
symptoms, and family accommodation all emerged as significant predictors.
For multiple reasons, including ethical, methodological, and financial, it is important to 
minimize the chances of including children in a failed clinical trial (ie, one that does not 
provide conclusive evidence for or against efficacy of the active treatment). One 
consequence of a higher-than-expected placebo response in a trial is to increase the chances 
of a signal being lost owing to lack of statistical power, resulting in a potentially useful 
treatment being passed over or discarded.38 Trials are extraordinarily expensive and time 
consuming to complete, and it is important that research efforts are undertaken with the 
greatest likelihood of success in detecting true differences between placebo and active 
treatment conditions.
The Studies to Advance Autism Research and Treatment (STAART) psychopharmacology 
network completed a trial of citalopram hydrobromide for the treatment of repetitive 
behavior in children with autism.11 We hypothesized that citalopram would produce 
significant global improvement, either by reducing interference associated with repetitive 
behaviors or by reducing anxiety and improving frustration tolerance or mood. In this large 
clinical trial, we found that there were just as many responders to placebo as to citalopram.11
In an effort to better understand the placebo response in autism, we were motivated to 
determine if there were predictors at the time of study entry that might distinguish 
participants who are more likely to respond generally and also whether there were factors 
that specifically influenced response to placebo vs citalopram. Identification of participant-
specific attributes that contribute to placebo responsiveness in autism will inform the design 
and interpretation of future studies to advance effective treatments for this complex disorder.
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A detailed description of the STAART citalopram trial has been published elsewhere.11 The 
clinical trial (NCT00086645) was registered at www.clinicaltrials.gov prior to initiation and 
con ducted at 6 academic medical centers: the Mount Sinai School of Medicine, New York, 
New York; the North Shore–Long Island Jewish Health System, Great Neck, New York; the 
Dartmouth-Hitchcock Medical Center, Lebanon, New Hampshire; UCLA; the University of 
North Carolina, Chapel Hill; and Yale University, New Haven, Connecticut. Each site’s 
institutional review board approved the study, and informed consent was obtained from all 
study participants and/or legal representatives. The National Institute of Mental Health 
convened a data and safety monitoring board that monitored the trial. The primary analyses 
showed that there was no significant difference in response on the Clinical Global 
Impression–Improvement sub-scale between the citalopram group (32.9% response rate) and 
the placebo group (34.2% responserate); the mean dose was 0.49 mg/kg (range, 0.07–1.26 
mg/kg) at week 12. There were no significant differences between citalopram and placebo 
groups on any of the secondary outcome measures.
Participants
A total of 149 children and adolescents between 5 and 17 years of age (mean [SD] age, 9.4 
[3.1] years) were randomly assigned to receive either citalopram (n = 73) (maximum up to 
20 mg/d) or placebo (n = 76) for 12 weeks.
Main Outcome Measures
Primary Outcome—The primary outcome was the same as the outcome used in the 
primary study by King et al.11 A responder (someone who had a positive clinical response) 
was defined by a Clinical Global Impression–Improvement39 score of 1 or 2 (much or very 
much improved compared with baseline) at week 12 by an evaluating clinician.
Baseline Predictors—The baseline predictors contain many of the same measures used 
as secondary outcomes (at week 12) in the primary study.11 Prior to randomization, the 
following symptom measures, including subscales for the child, were obtained: the Aberrant 
Behavior Checklist (ABC),40 Child and Adolescent Symptom Inventory (CASI),36 
Repetitive Behavior Scale–Revised,41 Children’s Yale-Brown Obsessive-Compulsive 
Scale,42 and Vineland Adaptive Behavior Scale subscale scores.43 All of the symptom 
measures were reported by the child’s guardian and reviewed by the evaluating clinician, 
masked to drug dose and side effects. The following data were obtained for the guardian: 
age, education, employment status, race, parity, and Caregiver Strain Questionnaire.44
Confounders—Potential baseline confounders included age, sex, race, severity of autism 
symptoms overall (using the Clinical Global Impression–Severity scale),39 vital signs, body 
mass index, pubertal status, IQ, medication history and concomitant services, study site, and 
presence of adverse events elicited from the Side-Effect Monitoring Uniform Report Form at 
study entry. Potential confounders that could affect response, particularly for those children 
randomly assigned to citalopram, included various measures of adverse effects. We created 
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adverse effect measures that reflected phenotype of disease, burden of disease, or any 
adverse effect that worsened by week 12 from baseline.
Statistical Analysis
The goal was to determine the baseline characteristics that influenced or predicted response 
at week 12. Because there were many candidate variables and overlap between variables 
with respect to substantive meaning, we performed a principal component analysis to reduce 
the number of tests performed (to minimize the effect of multiple testing by controlling the 
experimental P value) and to group like items for ease of interpretation. First, we 
investigated the relationship between each baseline measure/predictor and response at week 
12 based on responder status (ie, dichotomized Clinical Global Impression–Improvement 
score), in all participants and stratified by treatment group using either a t test or χ2 test, 
based on the type of baseline measure under investigation (continuous or categorical, 
respectively). Second, to ensure that there was no imbalance between treatment groups at 
baseline, the same analytic approach described in step 1 was used to compare each baseline 
predictor variable and each potential baseline confounder by treatment group at baseline. 
Third, a principal component analysis was performed using the significant baseline 
predictors from step 1. The number of components retained in the principal component 
analysis was determined by a combination of the eigenvalue greater than 1 rule and the 
percent variance–explained rule, as well as by substantive interpretation after both varimax 
and promax rotation. Fourth, based on the results of the principal component analysis, 
composite variables were created by standardizing each predictor variable and taking the 
mean value of the standardized predictor variables that uniquely loaded on a given 
component. Fifth, analysis of each composite variable predicting 12-week response, adjusted 
for relevant adverse effect confounders (after randomization through the study period), was 
performed using logistic regression analysis.
The effect modification (statistical interaction) between each composite measure (continuous 
and dichotomized at the median) and treatment group on response was investigated using 
multivariable logistic regression analysis. If there was significant statistical interaction, 
analyses were stratified by treatment group. Relative risks and 95% CIs were computed 
within the treatment group for each of the composite measures to summarize effect. Our 
study has 80% power to detect a relative risk as small as 2.4 in stratified analysis (within 
treatment groups), assuming a response as small as 20% in 1 group.
All analyses were performed in SAS version 9.2 (SAS Institute Inc). No adjustment was 
made for multiple testing because the analyses were exploratory in nature. Statistical 
significance was based on 2-sided tests and an α level of .05.
Results
Several of the individual baseline predictors were statistically related to response at week 12, 
primarily placebo response (eTable 1 in Supplement). Baseline predictors included ABC 
Hyperactivity and Irritability subscales; the CASI Attention-Deficit/Hyperactivity Disorder, 
Autism, Depression, Panic, Schizophrenia, Somatization, and Tic subscales; the Caregiver 
Strain Internalizing and Externalizing subscales; and the Vineland Socialization Domain 
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Standard Score. For all but the CASI Panic item score, the higher the symptom burden as 
reflected in the particular measure, the less likely the participant would be a responder to 
citalopram or placebo. There were no statistically significant differences between the 
proportions of responders for each of the baseline confounders, with the exception of body 
mass index (a lower body mass index predicted response), and we subsequently adjusted for 
body mass index in our analyses.
By including all of the baseline predictor variables listed in our principal component 
analyses, we found that 3 distinct components emerged, and from these components, we 
created 3 composite measures (Table). The first composite, Disruptive Behavior, is 
composed of ABC Hyperactivity, ABC Irritability, and CASI Attention-Deficit/
Hyperactivity Disorder scales; the second composite, Autism Severity/Mood, is composed 
of the CASI Autism and Depression scales; and the third composite, Caregiver Strain, is 
composed of the Caregiver Strain Questionnaire Externalized and Internalized scales. Our 
Table provides descriptive statistics for each of the composite measures by treatment group. 
Each composite measure was approximately normally distributed, and the theoretic range for 
each measure was between 0 and 100, in which a higher score indicates more symptoms. 
Each of the 3 composite measures was dichotomized at the median. The interaction between 
each composite measure and treatment group was significant or trended toward significance; 
thus, stratified analysis was performed. Placebo responders are statistically significantly less 
symptomatic on all 3 composite measures at baseline than nonresponders (all P < .013), and 
there are no statistically significant differences between each composite measure at baseline 
for those receiving citalopram (Table). Participants in the placebo group were less likely to 
respond if they entered the study with scores exceeding the median of Disruptive Behavior 
(relative risk, 2.0 [95% CI, 1.0–4.0]), Mood/Autism (relative risk, 2.5 [95% CI, 1.2–5.2]), or 
Caregiver Strain (relative risk, 2.5 [95% CI, 1.2–5.3]) composite measures (Figure 2). 
Adjustment for adverse effects during the trial did not modify the results.
An additional exploratory analysis was performed to determine whether response at week 12 
would be reflected differently if there was a threshold that would have limited the population 
of participants enrolled. Because our baseline predictors largely measured disruptive 
behaviors, we chose the Caregiver Strain composite as a hypothetical screener; thus, we 
retained participants whose guardians scored above the median on the Caregiver Strain 
composite. There are no statistically significant differences between the treatment and 
placebo groups in standard measures of repetitive behavior on response from baseline to 
week 12, although there is a trend in ABC Irritability subscale: most likely an issue with 
power (eTable 2 in Supplement).
Discussion
Because the STAART citalopram trial was among the largest multisite clinical trials in 
autism to date, the number of participants randomly assigned to each condition was 
sufficient to enable an analysis of factors at baseline that may predispose a participant to a 
placebo or nonspecific response. Interestingly, we found that several factors significantly 
predicted response to placebo but not to citalopram. These factors included the severity of 
certain disruptive behaviors (primarily hyperactivity at baseline), additional measures of 
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mood and autism symptom burden, and a measure of caregiver strain. In each case, higher 
scores were associated with lower placebo response. The items on the internalizing subscale 
of the Caregiver Strain Questionnaire include questions about caregiver mood and fatigue, 
and also questions that assess worry about the child’s and the family’s future. This subscale 
may thus serve as a proxy for reduced hopefulness or optimism at the time of study entry. In 
addition, the absence of a relatively higher frequency or intensity of challenging behaviors at 
study entry may also raise the bar for placebo response.
Similar to other studies that have implicated higher placebo response rates in childhood 
depression studies associated with milder illness severity at baseline,28 we found that all of 
the factors predicting a greater placebo response in this trial favored lower symptom burden. 
What appears to be different about our study is that the higher likelihood for response was 
exclusive to the placebo condition and not a more general predictor of response overall, and 
that the conditions that predisposed to a favorable response rate in the placebo condition 
seemed not to carry over to the citalopram condition.
Thus, in the lower half of the Disruptive Behavior, Mood/Autism, and Caregiver Strain 
component measures, 50% of participants responded at 12 weeks when treated with placebo, 
whereas only about 30% of participants responded at 12 weeks when treated with 
citalopram. It appeared as if citalopram actually got in the way of the placebo response for 
some participants. However, although the participants in the citalopram group had a 
significantly higher number of adverse effects than did the participants in the placebo group, 
the adverse effects were not significantly different above or below the median splits. It 
remains possible that a family’s tolerance for adverse effects is somehow different in the 
setting of milder or more severe behaviors or their associated strain, but we are unable to 
address that possibility in the present study.
Placebo response is known to vary by type of disorder.30 Different placebo responses among 
clinical trials with the same disorder may provide important information leading to better 
selection of study participants, thus enhancing both the validity and the precision of 
identifying effective treatments. Interestingly, not all randomized clinical trials with children 
with autism show evidence of a strong placebo responder effect (Figure 1). Rather than 
undermining the previous assertions, these exceptions compel us to better understand the 
factors at play. Improvements in our understanding of these effects will lead directly to 
potential mitigation strategies in the design and conduct of randomized clinical trials and, 
possibly, to improved and more efficient assessments of treatments and their availability for 
this patient population.
There was no benefit to citalopram (34% response rate) relative to placebo (32% response 
rate) regarding the primary and secondary outcome measures in the primary analyses.11 We 
investigated whether the subpopulation of participants in the citalopram group who scored in 
the upper half of the Caregiver Strain composite were different from the subpopulation of 
participants in the placebo group who also scored in the upper half of the Caregiver Strain 
composite, and it is interesting to highlight that none of the secondary outcomes at week 12 
from the primary analysis, with the possible exception of ABC Irritability, suggested a 
specific signal. This finding may indicate that the global improvement that was identified in 
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this subpopulation was unlikely to have been associated with a distinct change in repetitive 
behaviors and may have been due to changes that were not adequately captured in our 
ratings (eg, mood or anxiety symptoms). The fact that selective serotonin reuptake inhibitors 
such as citalopram are so widely prescribed for the population with autism may indeed 
suggest that clinicians and families are seeing benefits in areas other than repetitive behavior, 
which was the primary focus for recruitment into this trial.
To our knowledge, this is the first study of autism and child psychopharmacology to 
demonstrate factors that differentially predict the likelihood of response to placebo over that 
of an active drug. Replication of these findings may be applied to other large autism trials. 
The power of future trials may be significantly enhanced by taking these factors into 
account, and studies designed to attempt to replicate these findings should be a priority.
In conclusion, there is a clear recognition that children and adolescents with autism 
spectrum disorders have serious behavioral problems and psychiatric symptoms that may be 
appropriate targets for pharmacotherapy. Large-scale trials to guide clinical practice are 
expensive, time consuming, and relatively sparse.45 The results of our secondary analysis do 
not change the finding that citalopram appeared not to be specifically advantageous 
compared with placebo for the treatment of repetitive behaviors. However, this analysis does 
underscore the need to conduct trials that are adequately powered to look for informative 
subgroups, and it highlights the ongoing need for placebo-controlled trials of medications 
commonly used for children with autism spectrum disorders to determine whether the 
benefits of specific drugs substantially outweigh their risks.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1. Placebo Response in Randomized Clinical Trials of Autism and Related Disorders in 
Which a Dichotomous Response (eg, Responder vs Nonresponder) Was Reported
Oral IG indicates oral human immunoglobulin; ORG 2766, an adrenocorticotropic hormone 
(4–9) analog; and RUPP, Research Units on Pediatric Psychopharmacology Autism 
Network.
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Figure 2. Relationship Between Baseline Composite Predictor Measures Dichotomized at the 
Median and Response to Treatment at Week 12
The arrows, the relative risk (RR), and the corresponding 95% CI pertain to the placebo 
group and are interpreted as the likelihood of response if the participant entered the study 
with a composite score below the median value of Disruptive Behavior (A), Mood/Autism 
(B), and Caregiver Strain (C). Response to citalopram hydrobromide was not affected by the 
baseline predictor composite score.
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